During the past decade, Mannheimer Onkologie Praxis conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 2 clinical trials were completed, i.e. on average, 28.6% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mannheimer Onkologie Praxis" #1 sponsor was "German CLL Study Group" with 2 trials, followed by "University of Heidelberg Medical Center" with 2 trials sponsored, "Celgene" with 1 trials sponsored, "Takeda" with 1 trials sponsored and "Technische Universität Dresden" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mannheimer Onkologie Praxis" #1 collaborator was "Cancer Trials Ireland" with 2 trials as a collaborator, "Nordic CLL Study Group (NCLLSG)" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Mannheimer Onkologie Praxis" are "Multiple Myeloma" (3 trials), "Advanced Solid Tumors or Hematologic Malignancies" (1 trials), "Anemia" (1 trials), "B-cell Chronic Lymphocytic Leukemia" (1 trials) and "Chronic Lymphocytic Leukemia" (1 trials). Many other conditions were trialed in "Mannheimer Onkologie Praxis" in a lesser frequency.

Most popular intervention types in "Mannheimer Onkologie Praxis" are "Drug" (7 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lenalidomide" (3 trials), "Bortezomib" (2 trials), "Dexamethasone" (2 trials), "Ibrutinib" (2 trials) and "Obinutuzumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Mannheimer Onkologie Praxis" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Mannheimer Onkologie Praxis". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Mannheimer Onkologie Praxis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mannheimer Onkologie Praxis, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".